DEF: Leap Therapeutics Seeks Shareholder Approval for Capital & Nasdaq Compliance

Leap Therapeutics calls a special meeting to approve a significant share increase, a potential reverse stock split for Nasdaq compliance, and a new equity plan, following a $58.88 million private placement led by Winklevoss Capital.

Summary

• A special meeting of stockholders is scheduled for December 15, 2025, to vote on five key proposals.
• The company recently completed a private placement on October 8, 2025, raising approximately $58.88 million in gross proceeds.
• The private placement involved the sale of 15,212,311 shares of common stock, pre-funded warrants for up to 80,768,504 shares, and common warrants for up to 71,985,605 shares.
• Proceeds from the financing will be used for a digital asset treasury strategy, continued development of therapeutic programs (FL-501 and sirexatamab), transaction costs, working capital, and general corporate purposes.
• Stockholders will vote on increasing authorized shares from 250 million to 500 million (490 million common stock) to provide future issuance flexibility.
• A proposal for a reverse stock split, with a ratio between 1:5 and 1:20, is being sought to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• A new 2025 Equity Incentive Plan is proposed, authorizing 31,454,785 shares for grants, including an evergreen provision for annual increases.
• Approval is requested for the issuance of up to 152,754,109 shares upon warrant exercise from the private placement, which could exceed Nasdaq's 19.99% change of control threshold.
• The Board unanimously recommends voting FOR all proposals.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While a significant capital raise was achieved, it comes with substantial dilution and the immediate need for a reverse stock split to maintain Nasdaq listing, indicating underlying financial and market performance issues. The strategic shift to digital assets introduces high-risk, high-reward elements, but the core biopharma business faces ongoing development costs and recent executive terminations. The overall picture suggests a company in a challenging position, taking drastic measures to secure its future.

Positives

• Successfully completed a private placement raising approximately $58.88 million in gross proceeds, significantly improving the cash position.
• Secured Winklevoss Treasury Investments, LLC as a Lead Investor, bringing expertise for a digital asset treasury strategy.
• Proceeds will fund the continued development of therapeutic programs, including FL-501 and sirexatamab, which recently completed a Phase 2 trial in colorectal cancer.
• The proposed 2025 Equity Incentive Plan aims to attract, retain, and motivate key personnel by aligning their interests with stockholders through equity awards.

Negatives

• The company's common stock bid price was $0.447 per share as of October 31, 2025, below Nasdaq's $1.00 minimum requirement, necessitating a potential reverse stock split.
• Failure to approve the reverse stock split could lead to delisting from Nasdaq, which would have serious adverse effects.
• The issuance of shares upon exercise of private placement warrants will result in significant dilution for existing stockholders, potentially increasing outstanding shares by over 150 million.
• The market price of common stock after a reverse stock split may not rise proportionally or attract new investors, and could decline further.
• Two named executive officers, Augustine Lawlor (COO) and Cynthia Sirard (CMO), were terminated without cause in June and July 2025, respectively, due to a significant reduction in force.

Risks

• The Financing Transaction and related transactions may not be completed in a timely manner or at all.
• Failure to realize the anticipated benefits of the transactions and the proposed digital asset treasury strategy.
• Changes in business, market, financial, political, and regulatory conditions.
• Risks relating to the company's operations and business, including the highly volatile nature of cryptocurrency prices.
• The risk that the price of the company's common stock may be highly correlated to the price of the digital assets it holds.
• Risks related to increased competition in the industries in which the company does and will operate.
• Risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally.
• Risks relating to the treatment of crypto assets for U.S. and foreign tax purposes.
• Inability to comply with the continued listing requirements of the Nasdaq Capital Market, potentially leading to delisting.
• The reverse stock split may not result in a sustained increase in the per share price of common stock.
• The issuance of additional authorized but unissued shares after a reverse stock split could be dilutive to existing stockholders and cause a decline in the trading price.
• The market price of common stock will also be based on the performance of the company and other factors, some of which are unrelated to the number of shares outstanding.

Future Outlook

The company intends to use a portion of the recent $58.88 million private placement proceeds to pursue a digital asset treasury strategy, leveraging the expertise of Lead Investor Winklevoss Treasury Investments, LLC, with the aim of building long-term shareholder value. Additionally, capital will be allocated to continue the development of therapeutic programs, including FL-501 and sirexatamab, which recently completed a randomized controlled Phase 2 trial in colorectal cancer. The company also plans to regain compliance with Nasdaq's minimum bid price requirement by March 9, 2026, potentially through a reverse stock split.

Management Comments

• "This Financing Transaction has improved our cash position, and leveraging the expertise of Winklevoss Treasury Investments, LLC, as Lead Investor in the private placement (Winklevoss Capital), we aim to build long-term shareholder value through a digital asset treasury strategy."
• "A portion of the capital will be used to continue development of our therapeutic programs, including FL-501 and sirexatamab, which has recently completed a randomized controlled Phase 2 trial in patients with colorectal cancer."
• "Our Board unanimously recommends that stockholders vote FOR each of the Stockholder Proposals."
• "Our objective in effectuating the Reverse Stock Split is to attempt to raise the per-share trading price of our Common Stock to meet Nasdaq's continued listing requirements, which requires, among other things, that our Common Stock have a minimum per share bid price of $1.00 per share."
• "The Board also believes that a higher stock price may help generate investor interest in Leap among larger investment funds that have requirements around the minimum stock price of the companies that they own."
• "If the Reverse Stock Split successfully increases the per share price of our Common Stock, the Board also believes this may increase the dollar value of the trading volume in our Common Stock and facilitate future financings by the Company."
• "The Board has determined that it is very important that we continue to maintain an equity incentive plan that provides us with sufficient flexibility to create meaningful incentives for our senior executives and other employees."

Industry Context

Leap Therapeutics, a biopharmaceutical company, is navigating a challenging financial landscape, as evidenced by its declining cash balance and the need for a significant capital raise. The strategic pivot to include a 'digital asset treasury strategy' with Winklevoss Capital as a lead investor is a notable departure from traditional biopharma financing and investment strategies, potentially reflecting a search for alternative value creation in a difficult market for clinical-stage companies. This move could position Leap uniquely, but also introduces new risks associated with the volatile digital asset market. The continued development of therapeutic programs like sirexatamab (colorectal cancer) and FL-501 indicates ongoing commitment to its core biopharma mission, despite the financial pressures and management changes.

Comparison to Industry Standards

• The company's executive compensation program is designed to attract and retain a highly skilled team and align compensation with stockholder interests, a standard practice in the biopharmaceutical industry.
• The engagement of TenPas Consulting, LLC for market information and recommendations regarding executive and director compensation, including building a peer group of public oncology companies, aligns with industry best practices for compensation benchmarking.
• The need for a reverse stock split to regain Nasdaq compliance is a common challenge for smaller biopharmaceutical companies whose stock prices often fluctuate significantly based on clinical trial results and financing news. Many peer companies face similar listing challenges.
• The adoption of a new equity incentive plan (2025 EIP) is a standard mechanism for biopharmaceutical companies to provide long-term incentives and attract talent, especially given the long development cycles in the industry.

Management Changes

Corporate Governance

Related Party Transactions

• Winklevoss Treasury Investments, LLC (Winklevoss Capital) is the Lead Investor in the $58.88 million private placement and has the right to nominate two directors to the Board, one of whom shall act as chair, subject to beneficial ownership thresholds. This creates a significant influence and potential related party dynamic.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the exercise of warrants (over 150 million shares) and the proposed increase in authorized shares. The reverse stock split aims to prevent delisting, which would be positive, but carries risks of not sustaining a higher price. The digital asset strategy introduces new investment exposure and risk.
• **Employees**: Benefit from the proposed 2025 Equity Incentive Plan, which aims to provide meaningful incentives and aid in retention and recruitment. However, recent terminations of COO and CMO due to a 'significant reduction in force' indicate job insecurity for some.
• **Investors (Winklevoss Capital)**: Gains substantial equity ownership and significant influence over the Board, including the right to nominate directors and the Board chair, aligning their interests with the company's strategic direction, particularly the digital asset treasury strategy.
• **Nasdaq**: The company is actively seeking to regain compliance with listing requirements, which is positive for maintaining its public trading status and investor confidence.

Next Steps

• Hold a Special Meeting of Stockholders on December 15, 2025, to vote on five proposals.
• If approved, the company will amend its Charter to increase authorized shares from 250 million to 500 million.
• If approved, the Board will have discretion to effect a reverse stock split (1:5 to 1:20) within one year to regain Nasdaq compliance by March 9, 2026.
• If approved, the company will adopt the 2025 Equity Incentive Plan.
• If approved, the company will be permitted to issue shares in excess of 19.99% of outstanding common stock upon warrant exercise from the private placement.
• Continue development of therapeutic programs, including FL-501 and sirexatamab.
• Implement the digital asset treasury strategy with Winklevoss Capital.

Key Dates

Recommendation

The company has secured a substantial capital infusion, which is a positive for its immediate liquidity and continued therapeutic development. However, the need for a reverse stock split to maintain Nasdaq listing, coupled with significant potential dilution from warrant exercises, indicates underlying challenges and market skepticism. The new digital asset treasury strategy, while potentially innovative, introduces a new layer of risk and volatility. The recent executive terminations also signal operational restructuring. Given the mixed signals – a necessary capital raise and strategic shift against a backdrop of poor stock performance and dilution – a 'hold' recommendation is appropriate. Investors should monitor the success of the digital asset strategy, the impact of the reverse stock split on market perception, and the progress of its therapeutic pipeline before making further investment decisions.

Keywords

Biopharmaceutical, Digital Asset Treasury, SEC Filing, Proxy Statement, Nasdaq Compliance, Reverse Stock Split, Equity Incentive Plan, Private Placement, Warrants, Shareholder Vote, Corporate Governance, Oncology, Colorectal Cancer, FL-501, Sirexatamab, Winklevoss Capital